Technical limits of PET/CT with 18FDG in prostate cancer. No new perspectives in spite of optimised examination techniques;Technische grenzen des PET/CT mit 18FDG beim adenokarzinom der prostata. Trotz optimierter untersuchungstechnik keine neuen perspektiven

Aktuelle Urologie

Volumn 37, Issue 3, 2006, Pages 218-221

  Von Mallek, Dirk ^a   Backhaus, B ^a   Muller S C ^a   Matthies, A ^a   Palmedo, H ^a   Jaeger, U ^a   Biersack, H J ^a   Reinhardt, M ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

18FDG; PET CT; Prostate cancer; Staging

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE ENHANCEMENT; IMAGE PROCESSING; INSTRUMENTATION; LYMPH NODE; MALE; NEEDLE BIOPSY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; BIOPSY, NEEDLE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746864528     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932129     Document Type: Article

References (13)

1. 11C]Acetat- Positronen-emissionstomographie beim Prostatakarzinom. Urologe A 2002; 41: 569-576
2. Machtens S, Boerner AR, Hofmann M, Knapp WH, Jonas U. Positronen-emissionstomographie (PET) zur Diagnostik und zum Therapiemonitoring bei urologischen Tumoren. Urologe A 2004; 43: 1397-1409
3. Schöder H, Larson SM. Positron Emission Tomography for Prostate, Bladder, and Renal Cancer. Semin Nucl Med 2004; 34: 274-292
4. Antoch G, Beyer T, Freudenberg LS, Müller SP, Bockisch A, Debatin JF. PET/CT oder CT/PET? Die Perspektive eines Radiologen, elektromedica 2003; 71: 79-84
5. Miller K, Weißbach L (Hrsg). Leitlinie zur Therapie von Prostatakarzinome Urologe A 1999; 38: 63-639
6. 18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-629
7. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid H-P, Poppel H van, Wolff J, Zattoni F. EAU Guidelines on Prostate Cancer. Eur Urol 2005; 48: 546-551
8. Reske SN, Kotzerke J. FDG-PET for clinical use. Eur J Nucl Med 2001; 28: 1707-1723
9. Reinhardt MJ, Matthies A, Biersack HJ. PET-imaging in tumors of the reproductive trac. QJ Nucl Med 2002; 46: 105-112
10. Reinhardt MJ, Ehritt-Braun C, Vogelsang D, Ihling C, Högerle S, Mix M, Moser E, Krause TM. Metastatic Lymph Nodes in Patients with Cervical Cancer: Detection with MR Imaging and FDG PET. Radiology 2001; 218: 776-782
11. Mallek D von, Pöttgen C, Heintz M, Luebcke W, Schüle-Hein K, Kolkenbrock S, Pahlke-Berkowitz B, Sack H. Klinische Rektum-DVH-Evaluation bei Einsatz eines Ballonkatheters in der konformalen Strahlentherapie des Prostatakarzinoms. Strahlentherapie und Onkologie 2000; 176 (Suppl 1): 63
12. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 25-30
13. 18F- fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004; 31: 797